TaiGen Biopharmaceuticals Holdings Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 9.31 million compared to TWD 19.14 million a year ago. Net loss was TWD 8.55 million compared to net income of TWD 10.79 million a year ago. Basic loss per share from continuing operations was TWD 0.01 compared to basic earnings per share from continuing operations of TWD 0.02 a year ago.
For the nine months, sales was TWD 114.54 million compared to TWD 31.51 million a year ago. Net loss was TWD 48.94 million compared to TWD 124.9 million a year ago. Basic loss per share from continuing operations was TWD 0.07 compared to TWD 0.17 a year ago.